Kiniksa Pharmaceuticals, Ltd. updated earnings guidance for 2024. For the period, the company expects ARCALYST net product revenue of between $370 million and $390 million, compared to prior guidance of between $360 million and $380 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.77 USD | -1.69% | +1.23% | +12.71% |
14/05 | Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM | |
23/04 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.71% | 1.4B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Updates Earnings Guidance for 2024